FUJIFILM Diosynth Biotechnologies Appoints CEO

Steve Bagshaw, chief executive officer of FUJIFILM Diosynth Biotechnologies (FDB), has decided to retire from his current position, effective April 1, 2020. He will continue with the company in the role of non-executive Chairman and will assist with the transition in executive leadership.
 
Martin Meeson has been appointed to succeed Steve Bagshaw as chief executive officer. Mr. Meeson currently serves as president and chief operating officer of FUJIFILM Diosynth Biotechnologies, U.S.A., Inc.
 
Mr. Meeson is an accomplished industry executive and has played a key role in the growth and success of FDB. Mr. Meeson joined FDB in 2008 as director of finance, IT and supply chain for the UK site. In 2013 he moved to the North Carolina site as senior vice president of global finance. During this period, he was closely involved in the acquisition of FDB’s Texas facility. He was named president and chief operating officer of the U.S. operations in 2015.   
 
Before joining FDB, he was finance director at Oxford Chemicals where he was responsible for all aspects of finance, IT, and purchasing. He has also held leadership positions at Hibernia Foods, ICI/DuPont and KPMG.
 
"FDB has an exciting future ahead. I am delighted to see Martin take on the role of chief executive officer to lead the organization in its future growth" said Steve Bagshaw. "Martin has the skill set and experience to work with all of the FDB teams and our partners across the world to continue to deliver on our mission to advance tomorrow’s medicines."

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.